GlaxoSmithKline’s “Buy” Rating Reaffirmed at Societe Generale (GSK)
GlaxoSmithKline (LON: GSK)‘s stock had its “buy” rating restated by analysts at Societe Generale in a research report issued to clients and investors on Friday. They currently have a $27.44 (1810 GBX) price target on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday, January 30th. They now have a $22.06 price target on the stock. Separately, analysts at Barclays Capital upgraded shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research note to investors on Tuesday, January 29th. They now have a $23.70 price target on the stock.
Shares of GlaxoSmithKline opened at 1455.50 on Friday. GlaxoSmithKline has a one year low of GBX 1314.00 and a one year high of GBX 1556.50. The stock’s 50-day moving average is currently GBX 1437.31. The company’s market cap is £70.257 billion.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.